Global Medical REIT Inc.

GMRE
NYSEFree primer · Steps 1–3 of 21Coverage as of 2026-Q2
DCF Fair Value
$48+33.4%
Bull Case
GMRE trades at a material discount to NAV; rate cuts, accretive acquisitions, or multiple re-rating toward healthcare REIT peers are the primary upside drivers.
Bear Case
Tenant credit deterioration, CMS regulatory headwinds, or rising rates could widen GMRE's NAV discount further and pressure its high-yield dividend.

Full Research Available

This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.

View Investment MemoEach memo is $2. Coverage subscriptions for funds coming soon — join the waitlist.